Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Development of a PPRV challenge model in goats and its use to assess the efficacy of a PPR vaccine.

Enchery F, Hamers C, Kwiatek O, Gaillardet D, Montange C, Brunel H, Goutebroze S, Philippe-Reversat C, Libeau G, Hudelet P, Bataille A.

Vaccine. 2019 Mar 14;37(12):1667-1673. doi: 10.1016/j.vaccine.2019.01.057. Epub 2019 Feb 13.

2.

A foot-and-mouth disease SAT2 vaccine protects swine against experimental challenge with a homologous virus strain, irrespective of mild pathogenicity in this species.

Mouton L, Dekker A, Bleijenberg M, Blanchet M, Coco-Martin J, Hudelet P, Goutebroze S.

Vaccine. 2018 Apr 5;36(15):2020-2024. doi: 10.1016/j.vaccine.2018.02.096. Epub 2018 Mar 3.

3.

Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage.

Waters R, Ludi AB, Fowler VL, Wilsden G, Browning C, Gubbins S, Statham B, Bin-Tarif A, Mioulet V, King DJ, Colenutt C, Brown E, Hudelet P, King DP.

Vaccine. 2018 Mar 27;36(14):1901-1907. doi: 10.1016/j.vaccine.2018.02.016. Epub 2018 Mar 2.

4.

Development of a Double-Antigen Microsphere Immunoassay for Simultaneous Group and Serotype Detection of Bluetongue Virus Antibodies.

Breard E, Garnier A, Despres P, Blaise Boisseau S, Comtet L, Viarouge C, Bakkali-Kassimi L, Pourquier P, Hudelet P, Vitour D, Rossi S, Belbis G, Sailleau C, Zientara S.

Transbound Emerg Dis. 2017 Dec;64(6):1837-1847. doi: 10.1111/tbed.12578. Epub 2016 Sep 25.

PMID:
27667484
5.

The B-cell response to foot-and-mouth-disease virus in cattle following vaccination and live-virus challenge.

Grant CF, Carr BV, Singanallur NB, Morris J, Gubbins S, Hudelet P, Ilott M, Charreyre C, Vosloo W, Charleston B.

J Gen Virol. 2016 Sep;97(9):2201-9. doi: 10.1099/jgv.0.000517. Epub 2016 Jun 2.

6.

Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines.

Breard E, Belbis G, Viarouge C, Nomikou K, Haegeman A, De Clercq K, Hudelet P, Hamers C, Moreau F, Lilin T, Durand B, Mertens P, Vitour D, Sailleau C, Zientara S.

Vaccine. 2015 Jan 15;33(4):512-8. doi: 10.1016/j.vaccine.2014.11.053. Epub 2014 Dec 11.

PMID:
25500308
7.

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.

Nunes SF, Hamers C, Ratinier M, Shaw A, Brunet S, Hudelet P, Palmarini M.

J Virol. 2014 Nov;88(21):12222-32. doi: 10.1128/JVI.02183-14. Epub 2014 Aug 20.

8.

Interference of colostral antibodies with response to a Bluetongue serotype 8 inactivated vaccine in lambs born from hyperimmune ewes.

Leemans J, Hamers C, Chery R, Bibard A, Besancon L, Duboeuf M, Hudelet P, Goutebroze S, Kirschvink N.

Vaccine. 2013 Apr 8;31(15):1975-80. doi: 10.1016/j.vaccine.2013.02.005. Epub 2013 Feb 17.

PMID:
23422141
9.

Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment.

Shaw AE, Ratinier M, Nunes SF, Nomikou K, Caporale M, Golder M, Allan K, Hamers C, Hudelet P, Zientara S, Breard E, Mertens P, Palmarini M.

J Virol. 2013 Jan;87(1):543-57. doi: 10.1128/JVI.02266-12. Epub 2012 Oct 24.

10.

Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.

Bréard E, Belbis G, Hamers C, Moulin V, Lilin T, Moreau F, Millemann Y, Montange C, Sailleau C, Durand B, Desprat A, Viarouge C, Hoffmann B, de Smit H, Goutebroze S, Hudelet P, Zientara S.

Vaccine. 2011 Mar 16;29(13):2495-502. doi: 10.1016/j.vaccine.2010.12.105. Epub 2011 Jan 21.

PMID:
21256877
11.

Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle.

Hamers C, Galleau S, Chery R, Blanchet M, Besancon L, Cariou C, Werle-Lapostolle B, Hudelet P, Goutebroze S.

Vet Rec. 2009 Sep 26;165(13):369-73.

PMID:
19783850
12.

Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.

Hamers C, Rehbein S, Hudelet P, Blanchet M, Lapostolle B, Cariou C, Duboeuf M, Goutebroze S.

Vaccine. 2009 May 11;27(21):2789-93. doi: 10.1016/j.vaccine.2009.02.099. Epub 2009 Mar 10.

PMID:
19366576
13.

Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.

Savini G, Hamers C, Conte A, Migliaccio P, Bonfini B, Teodori L, Di Ventura M, Hudelet P, Schumacher C, Caporale V.

Vet Microbiol. 2009 Jan 1;133(1-2):1-8. doi: 10.1016/j.vetmic.2008.05.032. Epub 2008 Jun 8.

PMID:
18617335

Supplemental Content

Loading ...
Support Center